BOUNDLESS BIO, INC. Operating Expenses
BOUNDLESS BIO, INC. (BOLD) reported Operating Expenses of $24.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-07
- BOUNDLESS BIO, INC. operating expenses for the quarter ending 2026-06-30 was $24.38M, a 42.92% increase year-over-year.
- BOUNDLESS BIO, INC. operating expenses for the quarter ending 2026-03-31 was $14.47M, a 16.53% decline year-over-year.
- BOUNDLESS BIO, INC. operating expenses for the quarter ending 2025-12-31 was $14.00M, a 23.39% decline year-over-year.
- BOUNDLESS BIO, INC. operating expenses for the quarter ending 2025-09-30 was $15.15M, a 19.06% decline year-over-year.
- BOUNDLESS BIO, INC. operating expenses for fiscal 2025 was $63.55M, a 13.26% decline from fiscal 2024.
- BOUNDLESS BIO, INC. operating expenses for fiscal 2024 was $73.27M, a 33.71% increase from fiscal 2023.
- BOUNDLESS BIO, INC. operating expenses for fiscal 2023 was $54.80M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.38M 10-Q · filed 2026-08-07 | $38.86M 10-Q · filed 2026-08-07 | $52.86M derived: sum of 3 quarters · filed 2026-08-07 | $68.01M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $14.47M 10-Q · filed 2026-05-08 | $28.48M derived: sum of 2 quarters · filed 2026-05-08 | $43.63M derived: sum of 3 quarters · filed 2026-05-08 | $60.69M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $29.15M derived: sum of 2 quarters · filed 2026-03-09 | $46.21M derived: sum of 3 quarters · filed 2026-08-07 | $63.55M 10-K · filed 2026-03-09 |
| 2025-09-30 | $15.15M 10-Q · filed 2025-11-05 | $32.21M derived: sum of 2 quarters · filed 2026-08-07 | $49.55M 10-Q · filed 2025-11-05 | $67.83M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $17.06M 10-Q · filed 2026-08-07 | $34.40M 10-Q · filed 2026-08-07 | $52.68M derived: sum of 3 quarters · filed 2026-08-07 | $71.39M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $17.34M 10-Q · filed 2026-05-08 | $35.62M derived: sum of 2 quarters · filed 2026-05-08 | $54.33M derived: sum of 3 quarters · filed 2026-05-08 | $73.72M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $18.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $36.99M derived: sum of 2 quarters · filed 2026-03-09 | $56.38M derived: sum of 3 quarters · filed 2026-03-09 | $73.27M 10-K · filed 2026-03-09 |
| 2024-09-30 | $18.71M 10-Q · filed 2025-11-05 | $38.11M derived: sum of 2 quarters · filed 2025-11-05 | $54.99M 10-Q · filed 2025-11-05 | $68.78M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $19.39M 10-Q · filed 2025-08-05 | $36.27M 10-Q · filed 2025-08-05 | $50.07M derived: sum of 3 quarters · filed 2025-08-05 | $65.02M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $16.88M 10-Q · filed 2025-05-09 | $30.68M derived: sum of 2 quarters · filed 2025-05-09 | $45.63M derived: sum of 3 quarters · filed 2025-05-09 | $59.59M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $28.75M derived: sum of 2 quarters · filed 2025-03-27 | $42.71M derived: sum of 3 quarters · filed 2025-03-27 | $54.80M 10-K · filed 2025-03-27 |
| 2023-09-30 | $14.95M 10-Q · filed 2024-11-07 | $28.91M derived: sum of 2 quarters · filed 2024-11-07 | $41.00M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $13.96M 10-Q · filed 2024-08-12 | $26.05M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $12.09M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |